MLKL and systemic inflammatory response syndrome: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) regulates RIPK3-MLKL-driven systemic inflammation, and RIPK1 kinase inhibitors have shown promise in alleviating or preventing a SIRS response.